echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Summary of NCCN Clinical Practice Guidelines Chinese (October 2022)

    Summary of NCCN Clinical Practice Guidelines Chinese (October 2022)

    • Last Update: 2022-11-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Lung cancer

     

    NCCNClinical Practice Guidelines for Non-Small Cell Lung Cancer 2022.
    5 Edition(1)(Chinese)

    NCCNClinical Practice Guidelines for Non-small Cell Lung Cancer 2022.
    5 Edition (2) (Chinese)

    NCCNNon-small cell lung cancer guide mind map (1) (2021.
    7 version)

    NCCNNon-small cell lung cancer guide mind map (2) (2021.
    7 edition)

    Non-small cell lung cancer, a competition of treatment options at home and abroad (2022.
    5 version)

    NCCNClinical Practice Guidelines for Small Cell Lung Cancer 2023.
    1 Edition (Chinese)

    NCCNSmall Cell Lung Cancer Guide Mind Map (2022.
    2 Edition)

    Small cell lung cancer, a big competition of treatment options at home and abroad (2023.
    1 edition).

    Fleischner guidelines: Management of incidental pulmonary nodules detected by CT (1) (Chinese)

    Fleischner guidelines: management of incidental pulmonary nodules detected by CT (2) (Chinese)

    NCCNClinical Practice Guide: Lung Cancer Screening 2022.
    1 Version (Chinese)

     

    Solid tumors

    NCCNGlioma Patient Guide 2021 Edition (Chinese)

    NCCNClinical Practice Guidelines for Head and Neck Cancer 2022.
    2 Edition(1) (Chinese)

    NCCNClinical Practice Guidelines for Head and Neck Cancer 2022.
    2 Edition (2) (Chinese)

    NCCNBreast Cancer Clinical Practice Guidelines 2022.
    2 Edition (Chinese)

    NCCNThymoma and thymic cancer clinical practice guidelines 2022.
    1
    version (Chinese).

    NCCNClinical Practice Guidelines for Malignant Pleural Mesothelioma 2021.
    1 Edition (Chinese)

    NCCNClinical Practice Guidelines for Esophageal Cancer and Gastroesophageal Junction Cancer 2020.
    4 Edition(1) (Chinese)

    NCCNClinical Practice Guidelines for Esophageal Cancer and Gastroesophageal Junction Cancer 2020.
    4 Edition(2) (Chinese)

    NCCNGastric Cancer Clinical Practice Guidelines 2020.
    3 (Chinese)

    NCCNGastric Cancer Patient Guide 2019 Edition (Chinese)

    NCCNColon Cancer Clinical Practice Guidelines 2021.
    3 (Chinese)

    NCCNClinical Practice Guidelines for Rectal Cancer 2020.
    6 Edition(1) (Chinese)

    NCCNClinical Practice Guidelines for Rectal Cancer 2020.
    6 (2) (Chinese).

    NCCNColorectal Cancer Screening Guidelines 2021 (Chinese)

    NCCNProstate Cancer Clinical Practice Guidelines 2021.
    2 Edition (Chinese)

    NCCNMelanoma: Skin Clinical Practice Guidelines 2022.
    2 (Chinese)

    NCCNClinical Practice Guidelines for Soft Tissue Sarcoma 2020.
    2 (Chinese)

    tumor

    NCCNClinical Practice Guidelines for Acute Lymphoblastic Leukemia 2020.
    1 (Chinese)

    NCCNClinical Practice Guidelines for Childhood Acute Lymphoblastic Leukemia 2022.
    1 (Chinese)

    NCCNClinical Practice Guidelines for Acute Myeloid Leukemia 2022.
    2 (Chinese)

    NCCNClinical Practice Guidelines for Chronic Myeloid Leukemia 2020.
    2 (Chinese)

    NCCNClinical Practice Guidelines for Hairy Cell Leukemia 2021.
    1 (Chinese)

    NCCNClinical Practice Guidelines for Multiple Myeloma 2022.
    5 (Chinese)

    NCCNHodgkin Lymphoma Clinical Practice Guidelines 2021.
    4 (Chinese)

    NCCNClinical Practice Guidelines for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2022.
    3 (Chinese)

    NCCNClinical Practice Guidelines for T-Cell Lymphoma 2021.
    1 (Chinese)

    NCCNClinical Practice Guidelines for Primary Cutaneous Lymphoma 2022.
    2 (Chinese)

     

     

     

    Adverse events

     

     

    CTCAECommon adverse reactions in tumor treatment grade version 5.
    0

    NCCNGuidelines for the Management of Immunotherapy-Related Toxicities 2022.
    1 (1)(Chinese)

    NCCNGuidelines for the Management of Immunotherapy-Related Toxicities 2022.
    1 (2)(Chinese)

    NCCNAntiemetic Clinical Practice Guidelines 2022.
    1 Version (Chinese)

    NCCNClinical Practice Guidelines for Adult Cancer Pain 2022.
    1 Edition(1)(Chinese)

    NCCNClinical Practice Guidelines for Adult Cancer Pain 2022.
    1 Edition(2)(Chinese)

    NCCNHematopoietic Growth Factor Clinical Practice Guidelines 2022.
    1 Edition (Chinese)

    NCCNPrognosis of cancer-related infectionsGuidelines for Prevention and Treatment 2021.
    1 (1)(Chinese)

    NCCNGuidelines for the Prevention and Treatment of Cancer-Related Infections 2021.
    1 (2)(Chinese)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.